Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

NCT03377101 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped change in study design.

Conditions

Estrogen Receptor Positive
HER2/Neu Negative
Progesterone Receptor Positive
Stage IV Breast Cancer AJCC v6 and v7

Interventions

DRUG: Copanlisib
DRUG: Fulvestrant
OTHER: Laboratory Biomarker Analysis
DRUG: Palbociclib

Sponsor

National Cancer Institute (NCI)